Trial Outcomes & Findings for Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma (NCT NCT01238861)

NCT ID: NCT01238861

Last Updated: 2016-11-17

Results Overview

The annual asthma exacerbation rate (AER) was calculated as the total number of observed exacerbations in each group up to week 52, divided by total duration of person-year follow-up in each group. An asthma exacerbation is defined as a progressive increase of asthma symptoms (cough, wheeze, chest tightness, and/or shortness of breath) that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 days as prescribed or administered by the investigator or healthcare provider; or 2) participant initiation of systemic corticosteroids (tablets, suspension or injection) for a duration of at least 3 days as outlined in the Asthma Action Plan provided to the participant by the investigator on Day 1.

• Recruitment status: COMPLETED
• Study phase: PHASE2
• Target enrollment: 964 participants
• Primary outcome timeframe: Week 1 up to Week 52
• Results posted on: 2016-11-17

Participant Flow

Participants were stratified based on the protocol defined eosinophilic phenotype (EOS+ versus EOS-) and inhaled corticosteroid (ICS) use during a 3-week screening period. A total of 964 participants were screened out of which 609 were randomized in the study, and of which 606 participants received at least one dose of investigational product.

Participant milestones

Measure	Eosinophilic Phenotype (EOS+) Placebo EOS+ (defined as ELEN Index \[proprietary mathematical algorithm to predict sputum eosinophil's greater than or equal to 2 percent\] positive and/or FeNO \[fraction of exhaled nitric oxide\] greater than or equal to \[\>=\] 50 parts per billion \[ppb\]) participants received matching placebo subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 2 mg EOS+ participants received benralizumab 2 milligram (mg) subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 20 mg EOS+ participants received benralizumab 20 mg subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 100 mg EOS+ participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	Non-eosinophil Phenotype (EOS-) Placebo EOS- (defined as ELEN Index negative and FeNO \<50 ppb) participants received matching placebo subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Benralizumab, 100 mg EOS- participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
Overall Study STARTED	80	81	81	82	142	140
Overall Study COMPLETED	69	73	70	69	129	125
Overall Study NOT COMPLETED	11	8	11	13	13	15

Reasons for withdrawal

Measure	Eosinophilic Phenotype (EOS+) Placebo EOS+ (defined as ELEN Index \[proprietary mathematical algorithm to predict sputum eosinophil's greater than or equal to 2 percent\] positive and/or FeNO \[fraction of exhaled nitric oxide\] greater than or equal to \[\>=\] 50 parts per billion \[ppb\]) participants received matching placebo subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 2 mg EOS+ participants received benralizumab 2 milligram (mg) subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 20 mg EOS+ participants received benralizumab 20 mg subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 100 mg EOS+ participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	Non-eosinophil Phenotype (EOS-) Placebo EOS- (defined as ELEN Index negative and FeNO \<50 ppb) participants received matching placebo subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Benralizumab, 100 mg EOS- participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
Overall Study Lost to Follow-up	4	2	3	1	1	2
Overall Study Unplanned surgery	1	0	0	0	0	0
Overall Study Did not meet entry ACQ-6 criteria	0	0	1	0	1	1
Overall Study Incorrect enrollment/randomization	0	0	1	0	1	0
Overall Study Subject traveled to Argentina by 1 year	0	0	1	0	0	0
Overall Study Subject moved out of state/area	0	0	1	1	0	0
Overall Study Strongyloides stercoralis antibodies +	0	0	0	1	0	0
Overall Study Personal problems	0	0	0	1	0	0
Overall Study Unable to continue visits	0	0	0	1	0	1
Overall Study Serious adverse event	0	0	0	0	0	1
Overall Study Lack of compliance	0	0	0	0	0	1
Overall Study Adverse Event	0	1	0	0	0	0
Overall Study Withdrawal by Subject	6	5	4	8	10	9

Baseline Characteristics

Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma

Baseline characteristics by cohort

Measure	Eosinophilic Phenotype (EOS+) Placebo n=80 Participants EOS+ (defined as ELEN Index \[proprietary mathematical algorithm to predict sputum eosinophil's greater than or equal to 2 percent\] positive and/or FeNO \[fraction of exhaled nitric oxide\] greater than or equal to \[\>=\] 50 parts per billion \[ppb\]) participants received matching placebo subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 2 mg n=81 Participants EOS+ participants received benralizumab 2 milligram (mg) subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 20 mg n=81 Participants EOS+ participants received benralizumab 20 mg subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 100 mg n=82 Participants EOS+ participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	Non-eosinophil Phenotype (EOS-) Placebo n=142 Participants EOS- (defined as ELEN Index negative and FeNO \<50 ppb) participants received matching placebo subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Benralizumab, 100 mg n=140 Participants EOS- participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	Total n=606 Participants Total of all reporting groups
Age, Continuous	45.6 years STANDARD_DEVIATION 11.7 • n=5 Participants	47.1 years STANDARD_DEVIATION 12.8 • n=7 Participants	46.6 years STANDARD_DEVIATION 13.2 • n=5 Participants	47.8 years STANDARD_DEVIATION 12.9 • n=4 Participants	50.0 years STANDARD_DEVIATION 12.3 • n=21 Participants	50.0 years STANDARD_DEVIATION 11.5 • n=10 Participants	48.3 years STANDARD_DEVIATION 12.4 • n=115 Participants
Sex: Female, Male Female	53 Participants n=5 Participants	58 Participants n=7 Participants	48 Participants n=5 Participants	60 Participants n=4 Participants	100 Participants n=21 Participants	98 Participants n=10 Participants	417 Participants n=115 Participants
Sex: Female, Male Male	27 Participants n=5 Participants	23 Participants n=7 Participants	33 Participants n=5 Participants	22 Participants n=4 Participants	42 Participants n=21 Participants	42 Participants n=10 Participants	189 Participants n=115 Participants

PRIMARY outcome

Timeframe: Week 1 up to Week 52

Population: The modified intent-to-treat (mITT) population included all randomized participants who received any dose of investigational product.

The annual asthma exacerbation rate (AER) was calculated as the total number of observed exacerbations in each group up to week 52, divided by total duration of person-year follow-up in each group. An asthma exacerbation is defined as a progressive increase of asthma symptoms (cough, wheeze, chest tightness, and/or shortness of breath) that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 days as prescribed or administered by the investigator or healthcare provider; or 2) participant initiation of systemic corticosteroids (tablets, suspension or injection) for a duration of at least 3 days as outlined in the Asthma Action Plan provided to the participant by the investigator on Day 1.

Outcome measures

Measure	Eosinophilic Phenotype (EOS+) Placebo n=80 Participants EOS+ (defined as ELEN Index \[proprietary mathematical algorithm to predict sputum eosinophil's greater than or equal to 2 percent\] positive and/or FeNO \[fraction of exhaled nitric oxide\] greater than or equal to \[\>=\] 50 parts per billion \[ppb\]) participants received matching placebo subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 2 mg n=81 Participants EOS+ participants received benralizumab 2 milligram (mg) subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 20 mg n=81 Participants EOS+ participants received benralizumab 20 mg subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 100 mg n=82 Participants EOS+ participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Placebo EOS- (defined as ELEN Index negative and FeNO \<50 ppb) participants received matching placebo subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Benralizumab, 100 mg EOS- participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
Annual Asthma Exacerbation Rate (AER) for Eosinophilic Phenotype (EOS+) Participants	0.57 AER events/person-year	0.65 AER events/person-year	0.37 AER events/person-year	0.34 AER events/person-year	—	—

SECONDARY outcome

Timeframe: Baseline up to Week 66

Population: Due to change in planned analysis after unblinding of study data, dose response was not performed.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Pre-dose (0 hour), Post-dose on Day 1, 6, Week 4, 16, 24, 32, 40, and 52

Population: The Pharmacokinetic (PK) Population included all participants who received at least one dose of benralizumab and had at least one quantifiable PK observation. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for PK in the 100 mg benralizumab group.

Outcome measures

Measure	Eosinophilic Phenotype (EOS+) Placebo n=81 Participants EOS+ (defined as ELEN Index \[proprietary mathematical algorithm to predict sputum eosinophil's greater than or equal to 2 percent\] positive and/or FeNO \[fraction of exhaled nitric oxide\] greater than or equal to \[\>=\] 50 parts per billion \[ppb\]) participants received matching placebo subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 2 mg n=81 Participants EOS+ participants received benralizumab 2 milligram (mg) subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 20 mg n=223 Participants EOS+ participants received benralizumab 20 mg subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 100 mg EOS+ participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Placebo EOS- (defined as ELEN Index negative and FeNO \<50 ppb) participants received matching placebo subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Benralizumab, 100 mg EOS- participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
Minimum Observed Serum Trough Concentration for Benralizumab at Steady-State (Ctrough, ss)	34.7 microgram per milliliter Standard Deviation 131	182 microgram per milliliter Standard Deviation 180	869 microgram per milliliter Standard Deviation 665	—	—	—

SECONDARY outcome

Timeframe: Pre-dose (0 hour), Post-dose on Day 1, 6, Week 4, 16, 24, 32, 40, and 52

Population: The PK Population included all participants who received at least one dose of benralizumab and had at least one quantifiable PK observation. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for PK in the 100 mg benralizumab group.

Outcome measures

Measure	Eosinophilic Phenotype (EOS+) Placebo n=81 Participants EOS+ (defined as ELEN Index \[proprietary mathematical algorithm to predict sputum eosinophil's greater than or equal to 2 percent\] positive and/or FeNO \[fraction of exhaled nitric oxide\] greater than or equal to \[\>=\] 50 parts per billion \[ppb\]) participants received matching placebo subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 2 mg n=81 Participants EOS+ participants received benralizumab 2 milligram (mg) subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 20 mg n=223 Participants EOS+ participants received benralizumab 20 mg subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 100 mg EOS+ participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Placebo EOS- (defined as ELEN Index negative and FeNO \<50 ppb) participants received matching placebo subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Benralizumab, 100 mg EOS- participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
Dose-Normalized Minimum Observed Serum Trough Concentration for Benralizumab at Steady-State (Ctrough, ssD)	17.3 microgram per milliliter Standard Deviation 65.3	9.10 microgram per milliliter Standard Deviation 9.02	8.69 microgram per milliliter Standard Deviation 6.65	—	—	—

SECONDARY outcome

Timeframe: Baseline up to Week 92

Population: The mITT population included all randomized participants who received any dose of investigational product.

Immunogenicity assessment included determination of anti-drug (benralizumab) antibodies in serum samples. ADA positive was defined as a titer >=50 at any point in the study. It was observed at baseline and any visit during the study.

Outcome measures

Measure	Eosinophilic Phenotype (EOS+) Placebo n=80 Participants EOS+ (defined as ELEN Index \[proprietary mathematical algorithm to predict sputum eosinophil's greater than or equal to 2 percent\] positive and/or FeNO \[fraction of exhaled nitric oxide\] greater than or equal to \[\>=\] 50 parts per billion \[ppb\]) participants received matching placebo subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 2 mg n=81 Participants EOS+ participants received benralizumab 2 milligram (mg) subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 20 mg n=81 Participants EOS+ participants received benralizumab 20 mg subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 100 mg n=82 Participants EOS+ participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Placebo EOS- (defined as ELEN Index negative and FeNO \<50 ppb) participants received matching placebo subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Benralizumab, 100 mg EOS- participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
Percentage of Participants With Anti-Drug Antibodies (ADA) to Benralizumab in Eosinophilic Phenotype (EOS+) Participants	3.8 percentage of participants	42.0 percentage of participants	30.9 percentage of participants	25.6 percentage of participants	—	—

SECONDARY outcome

Timeframe: Baseline up to Week 52

Population: The mITT population included all randomized participants who received any dose of investigational product. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.

Asthma Control Questionnaire (ACQ) is a participant-reported questionnaire to assess the asthma control with 6 items assessing night-time waking, symptoms on waking, activity limitation, shortness of breath, wheeze, and rescue short-acting beta agonist use. Each item was rated on a 7-point Likert scale ranging from 0 (no impairment) to 6 (maximum impairment). Overall ACQ score was the mean of the 6 item scores with a score range of 0 (well controlled) to 6 (extremely poor controlled). Data collected on Day 1 prior to dosing was considered as baseline. Results were reported for overall ACQ score. ACQ-6 score was summarized together for all participants.

Outcome measures

Measure	Eosinophilic Phenotype (EOS+) Placebo n=80 Participants EOS+ (defined as ELEN Index \[proprietary mathematical algorithm to predict sputum eosinophil's greater than or equal to 2 percent\] positive and/or FeNO \[fraction of exhaled nitric oxide\] greater than or equal to \[\>=\] 50 parts per billion \[ppb\]) participants received matching placebo subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 2 mg n=81 Participants EOS+ participants received benralizumab 2 milligram (mg) subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 20 mg n=81 Participants EOS+ participants received benralizumab 20 mg subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 100 mg n=82 Participants EOS+ participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Placebo n=142 Participants EOS- (defined as ELEN Index negative and FeNO \<50 ppb) participants received matching placebo subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Benralizumab, 100 mg n=140 Participants EOS- participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
Change From Baseline in Asthma Control Questionnaire (6-items) (ACQ-6) Score at Week 52 Baseline (n=80,80,80,82,142,140)	2.7479 units on a scale Standard Deviation 0.9762	2.6479 units on a scale Standard Deviation 0.9908	2.4750 units on a scale Standard Deviation 0.9106	2.5346 units on a scale Standard Deviation 0.9728	2.4742 units on a scale Standard Deviation 0.8408	2.6381 units on a scale Standard Deviation 0.8330
Change From Baseline in Asthma Control Questionnaire (6-items) (ACQ-6) Score at Week 52 Change at Week 52 (n=34,42,40,39,64,73)	-0.8922 units on a scale Standard Deviation 1.1969	-1.1032 units on a scale Standard Deviation 1.1207	-1.2500 units on a scale Standard Deviation 1.2247	-1.1239 units on a scale Standard Deviation 1.2852	-0.8418 units on a scale Standard Deviation 1.1343	-1.1295 units on a scale Standard Deviation 1.1301

SECONDARY outcome

Timeframe: Baseline up to Week 52

Population: The mITT population included all randomized participants who received any dose of investigational product. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.

Total Nasal Symptoms Score (TNSS) is a 3-item questionnaire, the sum of nasal symptoms, namely, nasal obstruction (rhinorrhea), nasal congestion, and nasal itching/sneezing. Each symptom was rated on a scale from 0-3, with 0 representing no symptoms, 1 mild, 2 moderate, and 3 severe symptoms. TNSS score was a summation of the 3 individual nasal symptom. TNSS score could range from 0 to 9 where higher score indicates worsening. Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.

Outcome measures

Measure	Eosinophilic Phenotype (EOS+) Placebo n=222 Participants EOS+ (defined as ELEN Index \[proprietary mathematical algorithm to predict sputum eosinophil's greater than or equal to 2 percent\] positive and/or FeNO \[fraction of exhaled nitric oxide\] greater than or equal to \[\>=\] 50 parts per billion \[ppb\]) participants received matching placebo subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 2 mg n=81 Participants EOS+ participants received benralizumab 2 milligram (mg) subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 20 mg n=81 Participants EOS+ participants received benralizumab 20 mg subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 100 mg n=222 Participants EOS+ participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Placebo EOS- (defined as ELEN Index negative and FeNO \<50 ppb) participants received matching placebo subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Benralizumab, 100 mg EOS- participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
Change From Baseline in Mean Total Nasal Symptoms Score (TNSS) at Week 52 Baseline (n=71,27,25,81)	4.3 units on a scale Standard Deviation 2.0	4.8 units on a scale Standard Deviation 2.0	5.3 units on a scale Standard Deviation 1.8	4.4 units on a scale Standard Deviation 2.1	—	—
Change From Baseline in Mean Total Nasal Symptoms Score (TNSS) at Week 52 Change at Week 52 (n=89,39,39,106)	-0.4 units on a scale Standard Deviation 2.90	-0.8 units on a scale Standard Deviation 2.01	-1.0 units on a scale Standard Deviation 2.96	-0.8 units on a scale Standard Deviation 2.24	—	—

SECONDARY outcome

Timeframe: Baseline up to Week 51-52

Population: The mITT population included all randomized participants who received any dose of investigational product. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.

Asthma Symptom Diary included 7 questions about the participant symptom and the overall impact of treatment on the disease during the study period. Mean scores of the 7 questions were calculated to identify asthma symptom-free days. Asthma Symptom Diary Scores were analyzed on a bi-weekly basis and compared to baseline scores. Overall symptom score=(daytime frequency score + daytime severity score + nighttime severity score)/3, where total score ranges from 0 to 9. Higher score represents worsening. Mean asthma symptom diary score were summarized together for all participants. Mean asthma symptom diary score were summarized together for all participants. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.

Outcome measures

Measure	Eosinophilic Phenotype (EOS+) Placebo n=222 Participants EOS+ (defined as ELEN Index \[proprietary mathematical algorithm to predict sputum eosinophil's greater than or equal to 2 percent\] positive and/or FeNO \[fraction of exhaled nitric oxide\] greater than or equal to \[\>=\] 50 parts per billion \[ppb\]) participants received matching placebo subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 2 mg n=81 Participants EOS+ participants received benralizumab 2 milligram (mg) subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 20 mg n=81 Participants EOS+ participants received benralizumab 20 mg subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 100 mg n=222 Participants EOS+ participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Placebo EOS- (defined as ELEN Index negative and FeNO \<50 ppb) participants received matching placebo subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Benralizumab, 100 mg EOS- participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
Change From Baseline in Mean Asthma Symptom Diary Score at Week 51-52 Baseline (n=204,72,74,210)	1.58 units on a scale Standard Deviation 0.60	1.65 units on a scale Standard Deviation 0.65	1.60 units on a scale Standard Deviation 0.61	1.60 units on a scale Standard Deviation 0.62	—	—
Change From Baseline in Mean Asthma Symptom Diary Score at Week 51-52 Change at Week 51-52 (n=111,36,39,111)	-0.37 units on a scale Standard Deviation 0.61	-0.56 units on a scale Standard Deviation 0.76	-0.56 units on a scale Standard Deviation 0.69	-0.53 units on a scale Standard Deviation 0.67	—	—

SECONDARY outcome

Timeframe: Baseline up to Week 51-52

Population: The mITT population included all randomized participants who received any dose of investigational product. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively. Data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.

Participants were provided inhalers of the same dose (medium- or high-dose) inhaled corticosteroid (ICS) plus long-acting beta antagonist (LABA) combination product as baseline prophylactic medication and continued with same dose throughout the study. Rescue medications such as short-term beta2 agonists were used as first-line treatment for worsening asthma symptoms. Investigator prescribed additional short term asthma controller medications included additional ICS, theophylline, inhaled cromones or antimuscarinics; if asthma symptoms remained mild but not resolved. If asthma symptoms worsened, participants received an oral corticosteroid burst. All rescue medications use with prophylactic medication (+ prophylactic) and without prophylactic medication (- prophylactic) was recorded in asthma symptom dairy by participant. Rescue medication use was analyzed on a bi-weekly basis and compared to baseline scores.

Outcome measures

Measure	Eosinophilic Phenotype (EOS+) Placebo n=222 Participants EOS+ (defined as ELEN Index \[proprietary mathematical algorithm to predict sputum eosinophil's greater than or equal to 2 percent\] positive and/or FeNO \[fraction of exhaled nitric oxide\] greater than or equal to \[\>=\] 50 parts per billion \[ppb\]) participants received matching placebo subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 2 mg n=81 Participants EOS+ participants received benralizumab 2 milligram (mg) subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 20 mg n=81 Participants EOS+ participants received benralizumab 20 mg subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 100 mg n=222 Participants EOS+ participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Placebo EOS- (defined as ELEN Index negative and FeNO \<50 ppb) participants received matching placebo subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Benralizumab, 100 mg EOS- participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
Change From Baseline in Rescue Medication Use at Week 51-52 Change Week 51-52 -prophylactic(n=111,36,39,111)	-1.2540 rescue medication per 2 weeks Standard Deviation 2.4571	-1.4116 rescue medication per 2 weeks Standard Deviation 2.8722	-1.8804 rescue medication per 2 weeks Standard Deviation 5.3129	-1.1589 rescue medication per 2 weeks Standard Deviation 2.0086	—	—
Change From Baseline in Rescue Medication Use at Week 51-52 Baseline without prophylactic (n=204,72,74,210)	3.09 rescue medication per 2 weeks Standard Deviation 2.55	3.57 rescue medication per 2 weeks Standard Deviation 3.67	3.82 rescue medication per 2 weeks Standard Deviation 4.34	3.16 rescue medication per 2 weeks Standard Deviation 2.82	—	—
Change From Baseline in Rescue Medication Use at Week 51-52 Baseline with prophylactic (n=204,72,74,210)	4.07 rescue medication per 2 weeks Standard Deviation 3.34	4.71 rescue medication per 2 weeks Standard Deviation 5.56	5.24 rescue medication per 2 weeks Standard Deviation 6.40	4.22 rescue medication per 2 weeks Standard Deviation 3.90	—	—
Change From Baseline in Rescue Medication Use at Week 51-52 Change Week 51-52 +prophylactic(n=111,36,39,111)	-1.6855 rescue medication per 2 weeks Standard Deviation 3.2875	-1.6810 rescue medication per 2 weeks Standard Deviation 4.2247	-2.5118 rescue medication per 2 weeks Standard Deviation 7.6814	-1.4693 rescue medication per 2 weeks Standard Deviation 2.5603	—	—

SECONDARY outcome

Timeframe: Baseline and Week 52

Population: The mITT population included all randomized participants who received any dose of investigational product. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.

FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.

Outcome measures

Measure	Eosinophilic Phenotype (EOS+) Placebo n=222 Participants EOS+ (defined as ELEN Index \[proprietary mathematical algorithm to predict sputum eosinophil's greater than or equal to 2 percent\] positive and/or FeNO \[fraction of exhaled nitric oxide\] greater than or equal to \[\>=\] 50 parts per billion \[ppb\]) participants received matching placebo subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 2 mg n=81 Participants EOS+ participants received benralizumab 2 milligram (mg) subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 20 mg n=81 Participants EOS+ participants received benralizumab 20 mg subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 100 mg n=222 Participants EOS+ participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Placebo EOS- (defined as ELEN Index negative and FeNO \<50 ppb) participants received matching placebo subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Benralizumab, 100 mg EOS- participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 52 Baseline (n=215,80,81,218)	2.033 liters Standard Deviation 0.669	1.978 liters Standard Deviation 0.701	2.080 liters Standard Deviation 0.751	2.012 liters Standard Deviation 0.672	—	—
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 52 Change at Week 52 (n=150,51,58,160)	0.0098 liters Standard Deviation 0.3615	0.1631 liters Standard Deviation 0.4691	0.1847 liters Standard Deviation 0.5234	0.0998 liters Standard Deviation 0.3541	—	—

SECONDARY outcome

Timeframe: Baseline and Week 52

Population: The mITT population included all randomized participants who received any dose of investigational product. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.

Forced Vital Capacity (FVC) was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible.

Outcome measures

Measure	Eosinophilic Phenotype (EOS+) Placebo n=80 Participants EOS+ (defined as ELEN Index \[proprietary mathematical algorithm to predict sputum eosinophil's greater than or equal to 2 percent\] positive and/or FeNO \[fraction of exhaled nitric oxide\] greater than or equal to \[\>=\] 50 parts per billion \[ppb\]) participants received matching placebo subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 2 mg n=81 Participants EOS+ participants received benralizumab 2 milligram (mg) subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 20 mg n=81 Participants EOS+ participants received benralizumab 20 mg subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 100 mg n=82 Participants EOS+ participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Placebo n=142 Participants EOS- (defined as ELEN Index negative and FeNO \<50 ppb) participants received matching placebo subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Benralizumab, 100 mg n=140 Participants EOS- participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
Change From Baseline in Mean Forced Vital Capacity (FVC) at Week 52 Baseline (n=80,80,81,82,135,136)	3.282 liters Standard Deviation 1.030	3.069 liters Standard Deviation 0.957	3.285 liters Standard Deviation 1.028	3.110 liters Standard Deviation 0.851	3.043 liters Standard Deviation 0.864	3.126 liters Standard Deviation 0.981
Change From Baseline in Mean Forced Vital Capacity (FVC) at Week 52 Change at Week 52 (n=51,51,58,59,99,101)	0.029 liters Standard Deviation 0.514	0.129 liters Standard Deviation 0.565	0.190 liters Standard Deviation 0.586	0.166 liters Standard Deviation 0.445	-0.030 liters Standard Deviation 0.426	0.056 liters Standard Deviation 0.371

SECONDARY outcome

Timeframe: Baseline and Week 52

Population: The mITT population included all randomized participants who received any dose of investigational product. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.

The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed while sitting or standing prior to using any medication (if needed) for asthma. Home PEF was determined separately for morning and evening, and were averaged for each participant. Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.

Outcome measures

Measure	Eosinophilic Phenotype (EOS+) Placebo n=222 Participants EOS+ (defined as ELEN Index \[proprietary mathematical algorithm to predict sputum eosinophil's greater than or equal to 2 percent\] positive and/or FeNO \[fraction of exhaled nitric oxide\] greater than or equal to \[\>=\] 50 parts per billion \[ppb\]) participants received matching placebo subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 2 mg n=81 Participants EOS+ participants received benralizumab 2 milligram (mg) subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 20 mg n=81 Participants EOS+ participants received benralizumab 20 mg subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 100 mg n=222 Participants EOS+ participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Placebo EOS- (defined as ELEN Index negative and FeNO \<50 ppb) participants received matching placebo subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Benralizumab, 100 mg EOS- participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
Change From Baseline in Peak Expiratory Flow (PEF) at Week 52 Baseline (n=215,80,81,218)	319.3 liters per minute Standard Deviation 104.7	325.5 liters per minute Standard Deviation 101.6	323.1 liters per minute Standard Deviation 100.8	323.8 liters per minute Standard Deviation 101.7	—	—
Change From Baseline in Peak Expiratory Flow (PEF) at Week 52 Change at Week 52 (n=150,51,58,160)	13.0 liters per minute Standard Deviation 64.6	29.0 liters per minute Standard Deviation 64.1	45.9 liters per minute Standard Deviation 95.5	26.6 liters per minute Standard Deviation 66.3	—	—

SECONDARY outcome

Timeframe: Baseline and Week 52

Population: The mITT population included all randomized participants who received any dose of investigational product. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively. Data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.

AQLQ: a 32-item questionnaire evaluating quality of life of participants with asthma including 4 domains (symptoms, activity limitations, emotional function, and environmental stimuli). Participants were asked to recall their experiences during the previous 2 weeks and to score each of the 32 questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). The overall score was calculated as the mean response to all questions. The 4 domain scores were the means of the responses to the questions in each of the domains. Overall AQLQ score and 4 domain scores ranged from 7 (no impairment) to 1 (severe impairment). The AQLQ(S) responses were categorized as improvement (defined as change from baseline >=0.5), no change (defined as change from baseline >= -0.5 to less than [<] 0.5), and worse (defined as change from baseline < -0.5). Data was summarized by each treatment group.

Outcome measures

Measure	Eosinophilic Phenotype (EOS+) Placebo n=222 Participants EOS+ (defined as ELEN Index \[proprietary mathematical algorithm to predict sputum eosinophil's greater than or equal to 2 percent\] positive and/or FeNO \[fraction of exhaled nitric oxide\] greater than or equal to \[\>=\] 50 parts per billion \[ppb\]) participants received matching placebo subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 2 mg n=81 Participants EOS+ participants received benralizumab 2 milligram (mg) subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 20 mg n=81 Participants EOS+ participants received benralizumab 20 mg subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 100 mg n=222 Participants EOS+ participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Placebo EOS- (defined as ELEN Index negative and FeNO \<50 ppb) participants received matching placebo subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Benralizumab, 100 mg EOS- participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
Change From Baseline in Asthma Quality of Life Questionnaire (Standardized Version) (AQLQ[S]) Score at Week 52 Baseline (n=214,78,80,217)	3.72 units on a scale Standard Deviation 1.04	3.72 units on a scale Standard Deviation 1.17	3.79 units on a scale Standard Deviation 1.06	3.72 units on a scale Standard Deviation 1.01	—	—
Change From Baseline in Asthma Quality of Life Questionnaire (Standardized Version) (AQLQ[S]) Score at Week 52 Change at Week 52 (n=88,39,38,105)	0.9634 units on a scale Standard Deviation 1.3342	1.2612 units on a scale Standard Deviation 1.2082	1.4474 units on a scale Standard Deviation 1.4262	1.1223 units on a scale Standard Deviation 1.2636	—	—

SECONDARY outcome

Timeframe: Baseline and Week 52

Population: The mITT population included all randomized participants who received any dose of investigational product. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.

The utility-based EQ-5D questionnaire comprises of two parts and provides a generic measure of health for clinical and economic appraisal. The health state valuation was the summary score of mobility, self-care, usual activities, pain/discomfort and anxiety/depression on a 3 category scale (no problem, moderate problem, severe problems). Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.

Outcome measures

Measure	Eosinophilic Phenotype (EOS+) Placebo n=222 Participants EOS+ (defined as ELEN Index \[proprietary mathematical algorithm to predict sputum eosinophil's greater than or equal to 2 percent\] positive and/or FeNO \[fraction of exhaled nitric oxide\] greater than or equal to \[\>=\] 50 parts per billion \[ppb\]) participants received matching placebo subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 2 mg n=81 Participants EOS+ participants received benralizumab 2 milligram (mg) subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 20 mg n=81 Participants EOS+ participants received benralizumab 20 mg subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 100 mg n=222 Participants EOS+ participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Placebo EOS- (defined as ELEN Index negative and FeNO \<50 ppb) participants received matching placebo subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Benralizumab, 100 mg EOS- participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
Change From Baseline in European Quality of Life - 5 Dimensions (EQ-5D) Health State Evaluation at Week 52 Baseline (n=213,79,74,209)	0.7629 units on a scale Standard Deviation 0.2153	0.7418 units on a scale Standard Deviation 0.2376	0.7877 units on a scale Standard Deviation 0.1878	0.7679 units on a scale Standard Deviation 0.1623	—	—
Change From Baseline in European Quality of Life - 5 Dimensions (EQ-5D) Health State Evaluation at Week 52 Change at Week 52 (n=148,58,53,161)	0.0853 units on a scale Standard Deviation 0.2096	0.0822 units on a scale Standard Deviation 0.3137	0.1223 units on a scale Standard Deviation 0.2132	0.0824 units on a scale Standard Deviation 0.2179	—	—

SECONDARY outcome

Timeframe: Baseline and Week 52

Population: The mITT population included all randomized participants who received any dose of investigational product. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.

The utility-based EQ-5D questionnaire comprises of two parts and provides a generic measure of health for clinical and economic appraisal. The EQ-5D VAS was measured from 0 (worst imaginable health state) to 100 (best imaginable health state). Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.

Outcome measures

Measure	Eosinophilic Phenotype (EOS+) Placebo n=222 Participants EOS+ (defined as ELEN Index \[proprietary mathematical algorithm to predict sputum eosinophil's greater than or equal to 2 percent\] positive and/or FeNO \[fraction of exhaled nitric oxide\] greater than or equal to \[\>=\] 50 parts per billion \[ppb\]) participants received matching placebo subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 2 mg n=81 Participants EOS+ participants received benralizumab 2 milligram (mg) subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 20 mg n=81 Participants EOS+ participants received benralizumab 20 mg subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 100 mg n=222 Participants EOS+ participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Placebo EOS- (defined as ELEN Index negative and FeNO \<50 ppb) participants received matching placebo subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Benralizumab, 100 mg EOS- participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
Change From Baseline in EQ-5D Visual Analog Scale (VAS) at Week 52 Baseline (n=213,79,74,208)	65.0798 units on a scale Standard Deviation 17.8903	65.4937 units on a scale Standard Deviation 18.5063	64.3378 units on a scale Standard Deviation 18.1427	64.6250 units on a scale Standard Deviation 19.7778	—	—
Change From Baseline in EQ-5D Visual Analog Scale (VAS) at Week 52 Change at Week 52 (n=148,58,53,161)	12.8041 units on a scale Standard Deviation 19.1036	12.5517 units on a scale Standard Deviation 20.8008	15.4906 units on a scale Standard Deviation 21.7297	13.7391 units on a scale Standard Deviation 20.5139	—	—

SECONDARY outcome

Timeframe: Baseline up to Week 51-52

Population: The mITT population included all randomized participants who received any dose of investigational product. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.

Percentage of nocturnal awakening-free nights were analyzed on a bi-weekly basis and compared to baseline scores. Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.

Outcome measures

Measure	Eosinophilic Phenotype (EOS+) Placebo n=222 Participants EOS+ (defined as ELEN Index \[proprietary mathematical algorithm to predict sputum eosinophil's greater than or equal to 2 percent\] positive and/or FeNO \[fraction of exhaled nitric oxide\] greater than or equal to \[\>=\] 50 parts per billion \[ppb\]) participants received matching placebo subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 2 mg n=81 Participants EOS+ participants received benralizumab 2 milligram (mg) subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 20 mg n=81 Participants EOS+ participants received benralizumab 20 mg subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 100 mg n=222 Participants EOS+ participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Placebo EOS- (defined as ELEN Index negative and FeNO \<50 ppb) participants received matching placebo subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Benralizumab, 100 mg EOS- participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
Change From Baseline in Percentage of Nocturnal Awakening-Free Nights at Week 51-52 Baseline (n=204,72,74,210)	52.05 percent nocturnal awakening-free nights Standard Deviation 36.96	45.07 percent nocturnal awakening-free nights Standard Deviation 40.04	51.57 percent nocturnal awakening-free nights Standard Deviation 39.72	50.92 percent nocturnal awakening-free nights Standard Deviation 37.72	—	—
Change From Baseline in Percentage of Nocturnal Awakening-Free Nights at Week 51-52 Change at Week 51-52 (n=111,36,39,111)	19.7595 percent nocturnal awakening-free nights Standard Deviation 39.1388	27.1749 percent nocturnal awakening-free nights Standard Deviation 41.7342	29.6181 percent nocturnal awakening-free nights Standard Deviation 38.4315	23.3054 percent nocturnal awakening-free nights Standard Deviation 36.2761	—	—

SECONDARY outcome

Timeframe: Baseline up to Week 52

Population: The mITT population included all randomized participants who received any dose of investigational product. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.

Data was summarized by each treatment group. In addition, data was summarized together for "EOS+ and EOS- Placebo" arms and "EOS+ and EOS- benralizumab 100 mg" arms.

Outcome measures

Measure	Eosinophilic Phenotype (EOS+) Placebo n=222 Participants EOS+ (defined as ELEN Index \[proprietary mathematical algorithm to predict sputum eosinophil's greater than or equal to 2 percent\] positive and/or FeNO \[fraction of exhaled nitric oxide\] greater than or equal to \[\>=\] 50 parts per billion \[ppb\]) participants received matching placebo subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 2 mg n=81 Participants EOS+ participants received benralizumab 2 milligram (mg) subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 20 mg n=81 Participants EOS+ participants received benralizumab 20 mg subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS+ Benralizumab, 100 mg n=222 Participants EOS+ participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Placebo EOS- (defined as ELEN Index negative and FeNO \<50 ppb) participants received matching placebo subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.	EOS- Benralizumab, 100 mg EOS- participants received benralizumab 50 mg as two subcutaneous injections every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
Change From Baseline in Mean Fraction Exhaled Nitric Oxide (FeNO) at Week 52 Baseline (n=222,81,81,222)	26.88 parts per billion Standard Deviation 23.57	39.52 parts per billion Standard Deviation 32.67	40.79 parts per billion Standard Deviation 31.03	26.68 parts per billion Standard Deviation 23.10	—	—
Change From Baseline in Mean Fraction Exhaled Nitric Oxide (FeNO) at Week 52 Change at Week 52 (n=148,57,56,157)	1.2523 parts per billion Standard Deviation 16.0200	-3.2222 parts per billion Standard Deviation 33.2543	-6.1905 parts per billion Standard Deviation 30.1103	1.4384 parts per billion Standard Deviation 28.9090	—	—

Adverse Events

EOS POS Placebo

Serious events: 7 serious events

Other events: 44 other events

Deaths: 0 deaths

EOS POS Benralizumab 2 mg

Serious events: 10 serious events

Other events: 54 other events

Deaths: 0 deaths

EOS POS Benralizumab 20 mg

Serious events: 6 serious events

Other events: 57 other events

Deaths: 0 deaths

EOS POS Benralizumab 100 mg

Serious events: 6 serious events

Other events: 68 other events

Deaths: 0 deaths

EOS NEG Placebo

Serious events: 16 serious events

Other events: 94 other events

Deaths: 0 deaths

EOS NEG Benralizumab 100 mg

Serious events: 18 serious events

Other events: 93 other events

Deaths: 0 deaths

Serious adverse events

Measure	EOS POS Placebo n=80 participants at risk EOS+ participants received two placebo injections subcutaneously.	EOS POS Benralizumab 2 mg n=81 participants at risk EOS+ participants received single benralizumab 2 milligram (mg) injection followed by a single placebo injection subcutaneously.	EOS POS Benralizumab 20 mg n=81 participants at risk EOS+ participants received single benralizumab 20 mg injection followed by a single placebo injection subcutaneously.	EOS POS Benralizumab 100 mg n=82 participants at risk EOS+ participants received two benralizumab 50 mg injections subcutaneously.	EOS NEG Placebo n=141 participants at risk EOS- participants received two placebo injections subcutaneously.	EOS NEG Benralizumab 100 mg n=141 participants at risk EOS- participants received two benralizumab 50 mg injections subcutaneously.
Cardiac disorders Acute myocardial infarct	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	1.2% 1/81 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Cardiac disorders Atrial fibrillation	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Cardiac disorders Cardiac failure acute	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Cardiac disorders Myocardial ischaemia	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	2.5% 2/81 • Number of events 2 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Cardiac disorders Supraventricular tachyca	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Gastrointestinal disorders Abdominal hernia	1.2% 1/80 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Gastrointestinal disorders Abdominal pain	1.2% 1/80 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	1.2% 1/82 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 4 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Gastrointestinal disorders Gastrooesophageal reflux	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Gastrointestinal disorders Intestinal obstruction	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Hepatobiliary disorders Cholecystitis	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Hepatobiliary disorders Cholecystitis acute	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Immune system disorders Drug hypersensitivity	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	1.2% 1/82 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Infections and infestations Bronchitis	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Infections and infestations Cholecystitis infective	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Infections and infestations Eczema infected	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Infections and infestations Enteritis infectious	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Infections and infestations Gastritis viral	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	1.2% 1/82 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Infections and infestations Herpes zoster	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Infections and infestations Pneumonia	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	1.2% 1/81 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	1.2% 1/82 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 2 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	2.1% 3/141 • Number of events 3 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Injury, poisoning and procedural complications Abdominal wound dehiscen	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Metabolism and nutrition disorders Hypercholesterolaemia	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	1.2% 1/81 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	2.5% 2/81 • Number of events 2 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Musculoskeletal and connective tissue disorders Musculoskeletal pain	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	1.2% 1/81 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Musculoskeletal and connective tissue disorders Osteochondrosis	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	1.2% 1/81 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Musculoskeletal and connective tissue disorders Spinal osteoarthritis	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Fibrous histiocytoma	1.2% 1/80 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant melanoma	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Thyroid neoplasm	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	1.2% 1/81 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Nervous system disorders Convulsion	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	1.2% 1/81 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Nervous system disorders Grand mal convulsion	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	1.2% 1/81 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Nervous system disorders Ischaemic stroke	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Nervous system disorders Syncope	1.2% 1/80 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Psychiatric disorders Depression	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Psychiatric disorders Insomnia	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Respiratory, thoracic and mediastinal disorders Asthma	2.5% 2/80 • Number of events 2 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	2.5% 2/81 • Number of events 2 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	2.4% 2/82 • Number of events 3 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	5.7% 8/141 • Number of events 14 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	3.5% 5/141 • Number of events 5 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Respiratory, thoracic and mediastinal disorders Asthmatic crisis	1.2% 1/80 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	1.2% 1/81 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Respiratory, thoracic and mediastinal disorders Nasal polyps	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	1.2% 1/82 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Skin and subcutaneous tissue disorders Erythema nodosum	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	1.2% 1/81 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Skin and subcutaneous tissue disorders Urticaria	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Gastrointestinal disorders Umbilical hernia	1.2% 1/80 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Immune system disorders Anaphylactic reaction	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Infections and infestations Gastroenteritis	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Infections and infestations Lower respiratory tract	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Infections and infestations Post procedural cellulit	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	1.2% 1/81 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Infections and infestations Postoperative wound infe	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	1.2% 1/82 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Infections and infestations Tonsillitis bacterial	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	1.2% 1/82 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Injury, poisoning and procedural complications Ulna fracture	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	1.2% 1/81 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Uterine leiomyoma	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	1.2% 1/81 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	1.2% 1/82 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Respiratory, thoracic and mediastinal disorders Interstitial lung diseas	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Skin and subcutaneous tissue disorders Eczema	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Vascular disorders Hypertension	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	1.2% 1/82 • Number of events 3 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Vascular disorders Polyarteritis nodosa	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/82 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .

Other adverse events

Measure	EOS POS Placebo n=80 participants at risk EOS+ participants received two placebo injections subcutaneously.	EOS POS Benralizumab 2 mg n=81 participants at risk EOS+ participants received single benralizumab 2 milligram (mg) injection followed by a single placebo injection subcutaneously.	EOS POS Benralizumab 20 mg n=81 participants at risk EOS+ participants received single benralizumab 20 mg injection followed by a single placebo injection subcutaneously.	EOS POS Benralizumab 100 mg n=82 participants at risk EOS+ participants received two benralizumab 50 mg injections subcutaneously.	EOS NEG Placebo n=141 participants at risk EOS- participants received two placebo injections subcutaneously.	EOS NEG Benralizumab 100 mg n=141 participants at risk EOS- participants received two benralizumab 50 mg injections subcutaneously.
Nervous system disorders Headache	10.0% 8/80 • Number of events 13 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	9.9% 8/81 • Number of events 13 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	7.4% 6/81 • Number of events 10 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	11.0% 9/82 • Number of events 10 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	5.7% 8/141 • Number of events 9 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	9.2% 13/141 • Number of events 17 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Respiratory, thoracic and mediastinal disorders Asthma	37.5% 30/80 • Number of events 51 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	34.6% 28/81 • Number of events 59 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	29.6% 24/81 • Number of events 42 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	31.7% 26/82 • Number of events 36 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	29.8% 42/141 • Number of events 67 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	29.8% 42/141 • Number of events 77 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Respiratory, thoracic and mediastinal disorders Rhinitis allergic	3.8% 3/80 • Number of events 3 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	3.7% 3/81 • Number of events 5 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	9.9% 8/81 • Number of events 13 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	7.3% 6/82 • Number of events 8 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	2.8% 4/141 • Number of events 8 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	3.5% 5/141 • Number of events 11 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Vascular disorders Hypertension	1.2% 1/80 • Number of events 2 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	3.7% 3/81 • Number of events 3 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/81 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	3.7% 3/82 • Number of events 3 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	2.8% 4/141 • Number of events 4 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	7.1% 10/141 • Number of events 12 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
General disorders Injection site erythema	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	2.5% 2/81 • Number of events 2 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	2.5% 2/81 • Number of events 4 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	9.8% 8/82 • Number of events 17 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	7.1% 10/141 • Number of events 17 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Infections and infestations Influenza	5.0% 4/80 • Number of events 4 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	3.7% 3/81 • Number of events 5 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	8.6% 7/81 • Number of events 7 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	7.3% 6/82 • Number of events 6 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	7.1% 10/141 • Number of events 11 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	4.3% 6/141 • Number of events 6 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Infections and infestations Acute sinusitis	3.8% 3/80 • Number of events 7 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	4.9% 4/81 • Number of events 6 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	2.5% 2/81 • Number of events 2 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	3.7% 3/82 • Number of events 3 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	1.4% 2/141 • Number of events 4 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	4.3% 6/141 • Number of events 8 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Infections and infestations Sinusitis	3.8% 3/80 • Number of events 6 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	4.9% 4/81 • Number of events 7 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	3.7% 3/81 • Number of events 3 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	2.4% 2/82 • Number of events 3 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	1.4% 2/141 • Number of events 2 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.00% 0/141 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Gastrointestinal disorders Nausea	2.5% 2/80 • Number of events 3 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	3.7% 3/81 • Number of events 3 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	2.5% 2/81 • Number of events 2 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	1.2% 1/82 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	1.4% 2/141 • Number of events 2 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	1.4% 2/141 • Number of events 2 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
General disorders Injection site pain	0.00% 0/80 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	7.4% 6/81 • Number of events 6 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	4.9% 4/81 • Number of events 17 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	2.4% 2/82 • Number of events 3 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	4.3% 6/141 • Number of events 12 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	1.4% 2/141 • Number of events 4 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
General disorders Pyrexia	1.2% 1/80 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	4.9% 4/81 • Number of events 4 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	3.7% 3/81 • Number of events 3 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	1.2% 1/82 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	1.4% 2/141 • Number of events 2 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Infections and infestations Bronchitis	3.8% 3/80 • Number of events 4 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	9.9% 8/81 • Number of events 10 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	7.4% 6/81 • Number of events 8 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	3.7% 3/82 • Number of events 4 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	9.2% 13/141 • Number of events 20 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	6.4% 9/141 • Number of events 11 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Infections and infestations Nasopharyngitis	10.0% 8/80 • Number of events 13 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	13.6% 11/81 • Number of events 19 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	8.6% 7/81 • Number of events 13 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	15.9% 13/82 • Number of events 16 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	3.5% 5/141 • Number of events 6 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	9.2% 13/141 • Number of events 17 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Infections and infestations Pharyngitis	3.8% 3/80 • Number of events 3 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	9.9% 8/81 • Number of events 10 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	3.7% 3/81 • Number of events 3 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	8.5% 7/82 • Number of events 9 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	3.5% 5/141 • Number of events 5 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	4.3% 6/141 • Number of events 6 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Infections and infestations Rhinitis	3.8% 3/80 • Number of events 3 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	3.7% 3/81 • Number of events 3 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	3.7% 3/81 • Number of events 3 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	2.4% 2/82 • Number of events 3 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	3.5% 5/141 • Number of events 5 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	2.1% 3/141 • Number of events 7 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Infections and infestations Upper respiratory tract	5.0% 4/80 • Number of events 6 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	8.6% 7/81 • Number of events 12 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	8.6% 7/81 • Number of events 8 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	6.1% 5/82 • Number of events 6 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	7.1% 10/141 • Number of events 12 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	7.8% 11/141 • Number of events 14 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Infections and infestations Urinary tract infection	5.0% 4/80 • Number of events 4 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	2.5% 2/81 • Number of events 3 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	1.2% 1/81 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	3.7% 3/82 • Number of events 4 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	3.5% 5/141 • Number of events 5 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	2.1% 3/141 • Number of events 3 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Musculoskeletal and connective tissue disorders Arthralgia	1.2% 1/80 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	4.9% 4/81 • Number of events 5 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	6.2% 5/81 • Number of events 6 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	3.7% 3/82 • Number of events 3 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	2.1% 3/141 • Number of events 3 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Musculoskeletal and connective tissue disorders Back pain	3.8% 3/80 • Number of events 3 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	4.9% 4/81 • Number of events 4 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	2.5% 2/81 • Number of events 2 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	2.4% 2/82 • Number of events 4 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	2.1% 3/141 • Number of events 3 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .
Musculoskeletal and connective tissue disorders Myalgia	1.2% 1/80 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	2.5% 2/81 • Number of events 2 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	3.7% 3/81 • Number of events 3 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	2.4% 2/82 • Number of events 3 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	0.71% 1/141 • Number of events 1 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .	3.5% 5/141 • Number of events 5 • From initiation of investigational product administration up to Week 92 The safety population included all participants who received any investigational product and had safety data available for analysis. One participant, randomized to the EOS- placebo group received a single dose of 100 mg benralizumab on Week 16 and was analyzed for safety in the 100 mg benralizumab group .

Additional Information

Rene van der Merwe, MBChB, MFPM, Medical Officer

MedImmune, LLC

Phone: 301-398-0000

Email: vandermerwer@medimmune.com

Results disclosure agreements

• Principal investigator is a sponsor employee MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.
• Publication restrictions are in place

Restriction type: OTHER